Reference drugs for triple combination test drug in Russia [Design Issues]

posted by mittyri – Russia, 2019-11-15 22:29 (546 d 16:38 ago) – Posting: # 20811
Views: 3,594

Hi PharmCat!

» Anyway can be some exceptions when this rule not work. May be it can be orphan drugs or some individual cases or regulatory abuse.
"The exception that proves the rule"
Just what I have found in GRLS and that drugs were approved within a BE study against 2 Reference drugs
Amlodipine + Indapamide + Perindopril
Losartan + Amlodipine + Rosuvastatin
Indapamide + Rosuvastatin + Perindopril
(could be more, lazy to search)

I would not name it 'orphan' or 'individual' :-)
Generic companies did develop almost all attractive double combinations for cardiovasulcar diseases and were trying to expand to triple combinations.

Kind regards,

Complete thread:

 Admin contact
21,462 posts in 4,487 threads, 1,514 registered users;
online 27 (0 registered, 27 guests [including 23 identified bots]).
Forum time: Saturday 15:08 UTC (Europe/Vienna)

By all means let’s be open-minded, but not so open-minded
that our brains drop out.    Richard Dawkins

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz